Table 1 Clinicopathological characteristics of patients with or without UFUR maintenance after adjuvant chemotherapy for ypstage III rectal cancer
Variable Category | Patient number (%) of each category in variable | Patients with UFUR maintenance | |
|---|---|---|---|
Patient number (%) in each category | P value | ||
Age group | |||
< 65 years | 45 (44.1) | 26 (57.8) | 0.488 |
≥ 65 years | 57 (55.9) | 29 (50.9) | |
Sex | |||
Female | 43 (42.2) | 24 (55.8) | 0.743 |
Male | 59 (57.8) | 31 (52.5) | |
Tumor location | |||
< 6 cm | 46 (45.1) | 27 (58.7) | 0.381 |
≥ 6 cm | 56 (54.9) | 28 (50.0) | |
Serum CEA | |||
≥ 5 ng/mL | 45 (44.1) | 26 (57.8) | 0.548 |
< 5 ng/mL | 57 (55.9) | 29 (50.9) | |
Type of surgery | |||
LAR | 77 (75.5) | 42 (76.3) | 0.215 |
APR | 3 (2.9) | 3 (5.5) | |
Hartmann | 1 (1.0) | 1 (1.8) | |
ISR | 21 (20.6) | 9 (16.4) | |
Complication of surgery, Clavien-Dindo | |||
0 | 84 (82.4) | 47 (85.5) | 0.494 |
1 | 4 (3.9) | 1 (1.8) | |
2 | 6 (5.9) | 2 (3.6) | |
3 | 7 (6.9) | 4 (7.3) | |
4 | 1 (0.9) | 1 (1.8) | |
ypTNM stage | |||
IIIa | 9 (8.8) | 7 (77.8) | 0.313 |
IIIb | 65 (63.7) | 33 (50.8) | |
IIIc | 28 (27.5) | 15 (53.6) | |
ypTNM, T stage | |||
T2 | 14 (13.7) | 10 (71.4) | 0.198 |
T3 | 66 (64.7) | 36 (54.5) | |
T4 | 22 (21.6) | 9 (40.9) | |
ypTNM, N stage | |||
N1 | 60 (58.8) | 33 (55.0) | 0.794 |
N2 | 42 (41.2) | 22 (52.4) | |
Histologic type | |||
Adenocarcinoma | 90 (88.2) | 48 (53.3) | 0.872 |
Signet ring cell | 8 (7.8) | 5 (62.5) | |
Mucinous | 4 (3.9) | 2 (50.0) | |
Histologic grade | |||
Well/ Moderate | 70 (68.6) | 37 (52.9) | 0.750 |
Poorly | 32 (31.4) | 18 (56.3) | |
Number of ELN | |||
≥ 12 | 79 (77.5) | 42 (53.2) | 0.776 |
< 12 | 23 (22.5) | 13 (56.5) | |
Metastatic LNR | |||
≥ 0.3 | 40 (39.2) | 19 (47.5) | 0.296 |
< 0.3 | 62 (60.8) | 36 (58.1) | |
Regimen of Adjuvant Chemotherapy | |||
5FU/LV | 51 (50) | 24 (47.1) | 0.164 |
FOLFOX | 51 (50) | 31 (60.8) | |
ECOG (before treatment) | |||
0 | 32 (31.4) | 17 (53.1) | 0.362 |
1 | 63 (61.8) | 32 (50.8) | |
2 | 6 (5.9) | 6 (100) | |